Results 41 to 50 of about 7,313 (199)

Therapeutic Potentials of Ketamine and Esketamine in Obsessive–Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature [PDF]

, 2021
The obsessive–compulsive spectrum refers to disorders drawn from several diagnostic categories that share core features related to obsessive–compulsive disorder (OCD), such as obsessive thoughts, compulsive behaviors and anxiety.
Chiappini, Stefania, Collevecchio, Roberta, Di Carlo, Francesco, Di Giannantonio, Massimo, Di Muzio, Ilenia, D’Andrea, Giacomo, Martinotti, Giovanni, Miuli, Andrea, Mosca, Alessio, Pettorruso, Mauro, Sensi, Stefano L.   +10 more
core   +2 more sources

The efficacy of nasal administration of esketamine in patients having moderate-to-severe pain after preoperative CT-guided needle localization: a randomized, double-blind, placebo-controlled trial

Frontiers in Medicine
BackgroundWhether nasal administration of esketamine can provide effective analgesia is unclear in patients with acute pain after preoperative CT-guided needle localization.MethodsIn this double-blind, randomized, placebo-controlled trial, patients were ...
Jiangning Xu, Jin Jian, Jin Jian, Yunyun Zhang, Jingxiang Wu, Jingxiang Wu, Yuwei Qiu, Yuwei Qiu   +7 more
doaj   +1 more source

Rare but relevant: Ibogaine and cardiovascular complications—prolonged QT interval and ventricular arrhythmias

Addiction, EarlyView.
Abstract Revived interest in psychedelic‐assisted therapies has also renewed focus on ibogaine, a psychoactive alkaloid, for its notable anti‐addictive potential. Evidence from observational, open‐label, and limited randomized placebo‐controlled trials indicates that ibogaine and its metabolite noribogaine reduce craving and withdrawal symptoms in ...
Tibor Markus Brunt
wiley   +1 more source

Interventions to prevent postoperative neurocognitive complications: an umbrella review of meta‐analyses of randomised controlled trials

Anaesthesia, EarlyView.
Summary Introduction The certainty of the effectiveness of interventions to manage postoperative neurocognitive complications remains unclear. The objective of this umbrella review was to synthesise and evaluate the evidence for interventions aimed at reducing the incidence of peri‐operative neurocognitive complications.
Filippo D'Amico, Stefano Turi, Marco Manazza, Giuliana Lo Bianco, Giacomo Monti, Alberto Zangrillo, Giovanni Landoni, Luigi Beretta   +7 more
wiley   +1 more source

Respiratory depression in women receiving propofol/esketamine versus propofol/fentanyl for abortion surgery or curettage: a randomized clinical trial

Annals of Medicine
Background A combination of opioids with propofol is a popular approach to non-intubated general anaesthesia; however, this method usually results in higher incidence of respiratory depression.
Cuiwen Zhang, Jiaxin Luo, Yeqing Liao, Huiyu Cao, Xiaoshan Wu, Xiaofang Huang, Hongmeng Lan, Yuliu Lin, Huihe Chen, Xuehai Guan   +9 more
doaj   +1 more source

Median effective dose (ED50) of esketamine combined with propofol for children to inhibit response of gastroscope insertion

BMC Anesthesiology, 2023
Background Propofol is the most commonly used drug for procedural sedation during gastroscopy. However, independent use of propofol can lead to increased dosage and additional side effects.
Ming Su, Yichao Zhu, Shupeng Liu, Lijuan Song, Jiangtao Qu, Yong Zhang, Quanyi Zhang   +6 more
doaj   +1 more source

How effective are ketamine or esketamine in treatment-resistant depression?

European Psychiatry, 2021
Introduction Globally, depression affects millions of individuals. A third of depression patients meet the criteria for treatment-resistant depression (TRD). The N-methyl-D-aspartate receptor antagonist, ketamine, improved depressive symptoms in a span
N. Veluri, Z. Mansuri
doaj   +1 more source

Are we repeating mistakes of the past? A review of the evidence for esketamine [PDF]

, 2020
Esketamine has been licensed for 'treatment-resistant depression' in the USA, UK and Europe. Licensing trials did not establish efficacy: two trials were negative, one showed a statistically significant but clinically uncertain effect, and a flawed ...
Horowitz, MA, Moncrieff, J
core  

Long-Term Efficacy of Intranasal Esketamine in Treatment-Resistant Major Depression: A Systematic Review [PDF]

, 2021
Esketamine (ESK) has been approved as a rapid-acting intranasal treatment for treatment-resistant depression (TRD). Although existing studies have investigated the efficacy of ESK in the 4-week induction phase, our knowledge about long-term ESK efficacy ...
Buoli M, Caldiroli A, Capellazzi M, Capuzzi E, Clerici M, Colmegna F, Dakanalis A., Marcatili M, Tagliabue I   +8 more
core   +1 more source

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology, EarlyView.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source